Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

This study has been terminated.
(Trial was terminated due to the need to re-formulate the study drug.)
Agensys, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: January 1, 2009
Last updated: February 26, 2013
Last verified: May 2010
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2010
  Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)